Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Inclusion Criteria:

Documented informed consent of participant and/or legally authorized representative

Agreement to allow the use of archival tissue from diagnostic tumor biopsies will be retrieved and submitted post-enrollment

If unavailable, exceptions may be granted with study principal investigator (PI) approval.
Eastern Cooperative Oncology Group (ECOG) status =< 2

Histologically confirmed mature peripheral T-cell or natural killer (NK)-cell lymphoma per World Health Organization (WHO) classification, including:

Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) with international protein index (IPI) of 2 or higher (must have bulky [defined as mass >= 10 cm] stage II, or stage III-IV disease)

ALK-negative ALCL

NOTE: Per amendment dated 05-10-19, ALCL will no longer be eligible except for Canada.
PTCL-not otherwise specified (NOS)
Angioimmunoblastic T-cell lymphoma (AITL)
Adult T-cell lymphoma/leukemia (ATLL)
Enteropathy-associated T-cell lymphoma (EATL)
Hepatosplenic T-cell lymphoma
CD30-positivity (e.g. at least 1%) by immunohistochemistry confirmed by hematopathology review at the participating institution
Measurable disease of at least 1.5 cm on computed tomography (CT) or positron emission tomography (PET)-CT scan

Absolute neutrophil count (ANC) >= 1,000/mm^3

Exception: unless documented bone marrow involvement by lymphoma

Platelets >= 50,000/mm^3

Exception: unless documented bone marrow involvement by lymphoma
Total serum bilirubin =< 1.5 x upper limit of normal (ULN) OR if hepatic involvement by lymphoma: =< 3 x ULN for Gilbert's disease or documented hepatic involvement by lymphoma
Aspartate aminotransferase (AST) =< 2 x ULN OR if hepatic involvement by lymphoma: AST =< 5 x ULN
Alanine aminotransferase (ALT) =< 2 x ULN OR if hepatic involvement by lymphoma: ALT =< 5 x ULN
Creatinine clearance of >= 60 mL/min per the Cockcroft-Gault formula
Left ventricular ejection fraction (LVEF) >= 45%
Women of childbearing potential (WOCBP): negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
Agreement by WOCBP and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy; childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

Exclusion Criteria:

Prior treatment of PTCL with systemic anti-lymphoma therapies, investigational agents, radiation

Exception: May have received 1 cycle of CHOP-like therapy (e.g. CHOP, CHOEP, EPOCH) or 1 cycle of CHP-BV; these participants must initiate day 1 cycle 1 of study therapy (CHEP-BV) no less than 19 days from prior CHOP-like or CHP-BV therapy; Patients who received 1 cycle of CHOP-like or 1 cycle of CHP-BV therapy prior to initiating induction with CHEP-BV are allowed to receive only 5 cycles of CHEP-BV instead of 6 cycles, per investigator's discretion

History of another primary invasive cancer, hematologic malignancy, or myelodysplastic syndrome that has not been in remission for at least 3 years.

Exceptions: Non-melanoma skin cancer and in situ cervical cancer
Symptomatic cardiac disease (including symptomatic ventricular dysfunction, symptomatic coronary artery disease, and symptomatic arrhythmias), cerebrovascular event/stroke or myocardial infarction within the past 6 months
Central nervous system involvement by lymphoma, including leptomeningeal involvement
History of progressive multifocal leukoencephalopathy (PML)
Active >= grade 3 viral, bacterial, or fungal infection within 2 weeks prior to day 1 of protocol therapy
Any known human immunodeficiency virus (HIV) infection, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection
Baseline peripheral neuropathy >= grade 2 or patients with the demyelinating form of Charcot-Marie-Tooth syndrome
Known severe hypersensitivity to any study related agent excipient(s)
Females only: pregnant or breastfeeding
Any other condition that would, in the investigator's judgement, contraindicate the patient's participation in the clinical study
Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)